pteridines has been researched along with Recrudescence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Müller-Tidow, C | 1 |
| Bug, G | 1 |
| Lübbert, M | 1 |
| Krämer, A | 1 |
| Krauter, J | 1 |
| Valent, P | 1 |
| Nachbaur, D | 1 |
| Berdel, WE | 1 |
| Ottmann, OG | 1 |
| Fritsch, H | 2 |
| Munzert, G | 2 |
| Garin-Chesa, P | 1 |
| Fleischer, F | 1 |
| Taube, T | 1 |
| Döhner, H | 1 |
| Awad, MM | 1 |
| Chu, QS | 1 |
| Gandhi, L | 1 |
| Stephenson, JJ | 1 |
| Govindan, R | 1 |
| Bradford, DS | 1 |
| Bonomi, PD | 1 |
| Ellison, DM | 1 |
| Eaton, KD | 1 |
| Johnson, BE | 1 |
| Socinski, MA | 1 |
2 trials available for pteridines and Recrudescence
| Article | Year |
|---|---|
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle Proteins; Drug Administratio | 2013 |
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
Topics: Administration, Intravenous; Adult; Aged; Cell Cycle Proteins; Disease-Free Survival; Female; Humans | 2017 |